Utilizing these innovative methods, the investigators discovered a network
of cell-to-cell communication driving scarring as the liver disease
advances.Researchers have uncovered novel candidate drug targets for non-alcoholic
fatty liver disease by using the latest technologies, including both
single-nuclear sequencing of mice and human liver tissue and advanced 3D
glass imaging of mice to characterize key scar-producing liver cells.
Utilizing these innovative methods, the investigators discovered a network
of cell-to-cell communication driving scarring as the liver disease
advances. The findings, published in Science Translational Medicine, could
lead to new treatments.In the United States, 30 to 40 per cent of adults are estimated to be
affected, with about 20 per cent of these patients having a more advanced
stage called non-alcoholic steatohepatitis, which is marked by liver
inflammation and may progress to advanced scarring (cirrhosis).
of cell-to-cell communication driving scarring as the liver disease
advances.Researchers have uncovered novel candidate drug targets for non-alcoholic
fatty liver disease by using the latest technologies, including both
single-nuclear sequencing of mice and human liver tissue and advanced 3D
glass imaging of mice to characterize key scar-producing liver cells.
Utilizing these innovative methods, the investigators discovered a network
of cell-to-cell communication driving scarring as the liver disease
advances. The findings, published in Science Translational Medicine, could
lead to new treatments.In the United States, 30 to 40 per cent of adults are estimated to be
affected, with about 20 per cent of these patients having a more advanced
stage called non-alcoholic steatohepatitis, which is marked by liver
inflammation and may progress to advanced scarring (cirrhosis).
